September 21, 2020
Institutional Review Board, Hospital for Special Surgery
The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.
For further information, see Understanding Clinical Trials/Research Studies.
Jillian Rose, PhD, MPH, LCSW
Adena Batterman, MSW, LCSW
Melissa Flores, LCSW
Roberta Horton, LCSW, ACSW
Juliette Kleinman, LCSW, ACSW
Adena Batterman, MSW, LCSW
Mavis Seehaus, MS, LCSW
Roberta Horton, LCSW, ACSW
This is a needs assessment study conducted via HIPAA-compliant online survey platform to understand the psychosocial impact of the COVID-19 pandemic on the rheumatic patient experience including: self-reported physical health, mental health, illness management, access to care, social environment, access to social services, emotional support and other resources. To participate, study enrollees complete a one-time 20-minute online questionnaire. Maximum enrollment is 300 and the enrollment period is from July 2020 to October 2020
Inclusion Criteria:
Participants must be over the age of 18 and diagnosed with a rheumatic condition and currently speaking English and/or Spanish.
Exclusion Criteria:
People under the age of 18 and/or who are not diagnosed with a rheumatic condition who speak a language other than English and/or Spanish.